Letairis (ambrisentan; Gilead/GlaxoSmithKline) is a selective endothelin type A receptor antagonist. Endothelin is a potent vasoconstrictor with mitogenic, hypertrophic, and pro-inflammatory properties. By preventing endothelin from binding to the endothelin receptor, Letairis blocks the receptor-mediated vasoconstriction of vascular smooth muscle cells.
While second-to-market Letairis (ambrisentan; Gilead/GlaxoSmithKline) has not managed to exceed the historical peak sales of fellow endothelin receptor antagonist (ERA) Tracleer (bosentan; Johnson & Johnson), it has remained a market-leading drug. Given that Letairis will imminently face generic competition in the US in October 2018, with other markets shortly following, the drug has limited opportunities for further uptake within the pulmonary hypertension (PH) market. Nonetheless, Letairis is expected to continue to benefit from the increasing adoption of ERAs in combination with phosphodiesterase 5 (PDE5) inhibitors based on the AMBITION trial. This will counterbalance some generic erosion and aid in maintaining steady sales despite intensifying competition.
4 Drug Overview
5 Product Profiles
LIST OF FIGURES
5 Letairis : Pulmonary hypertension
9 Figure 1: Letairis for pulmonary hypertension – SWOT analysis
10 Figure 2: Datamonitor Healthcare’s drug assessment summary of Letairis for pulmonary hypertension
11 Figure 3: Datamonitor Healthcare’s drug assessment summary of Letairis for pulmonary hypertension
13 Figure 4: Letairis sales for pulmonary hypertension across the US, Japan, and five major EU markets, by country, 2016–25
LIST OF TABLES
5 Table 1: Letairis drug profile
7 Table 2: Letairis pivotal trial data in pulmonary arterial hypertension
14 Table 3: Letairis sales for pulmonary hypertension across the US, Japan, and five major EU markets, by country ($m),
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.